Literature DB >> 11724274

Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART.

E Caride1, K Hertogs, B Larder, P Dehertogh, R Brindeiro, E Machado, C A de Sá, W A Eyer-Silva, F S Sion, L F Passioni, J A Menezes, A R Calazans, A Tanuri.   

Abstract

We have investigated the phenotypic and genotypic susceptibility of 14 HIV-1 strains isolated from individuals failing HAART therapy to protease inhibitors (PI). Proviral and plasma viral pol gene fragment were amplified, sequenced and subtyped. Nine samples clustered with protease subtype B reference strains and the remaining samples were classified as non-B subtype corresponding to subtype F (n = 4) and subtype A (n = 1). Although all patients were treated with similar P1 drug regimen, the non-B subtype isolates did not present the L90M and 184V mutations and used mainly G48V and V82A/F to achieve drug resistance. A strong cross-resistance phenotype among all four PI was associated with the mutation L90M in the subtype-B isolates, and with G48V and V82A/F in the non-B counterparts. This observation revealed that the non-B viruses tested had specific genotypic characteristics contrasting with the subtype-B isolates.

Entities:  

Mesh:

Year:  2001        PMID: 11724274     DOI: 10.1023/a:1011812810397

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  40 in total

1.  Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults.

Authors:  G Becker-Pergola; P Kataaha; L Johnston-Dow; S Fung; J B Jackson; S H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2000-05-20       Impact factor: 2.205

2.  Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.

Authors:  D Descamps; G Collin; F Letourneur; C Apetrei; F Damond; I Loussert-Ajaka; F Simon; S Saragosti; F Brun-Vézinet
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors.

Authors:  D Descamps; C Apetrei; G Collin; F Damond; F Simon; F Brun-Vézinet
Journal:  AIDS       Date:  1998-06-18       Impact factor: 4.177

4.  Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.

Authors:  S Palmer; A Alaeus; J Albert; S Cox
Journal:  AIDS Res Hum Retroviruses       Date:  1998-01-20       Impact factor: 2.205

5.  Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals.

Authors:  R Brindeiro; B Vanderborght; E Caride; L Correa; R M Oravec; O Berro; L Stuyver; A Tanuri
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  The neighbor-joining method: a new method for reconstructing phylogenetic trees.

Authors:  N Saitou; M Nei
Journal:  Mol Biol Evol       Date:  1987-07       Impact factor: 16.240

7.  HIV-1 patients may harbor viruses of different phylogenetic subtypes: implications for the evolution of the HIV/AIDS pandemic.

Authors:  D Pieniazek; L M Janini; A Ramos; A Tanuri; M Schechter; J M Peralta; A C Vicente; N K Pieniazek; G Schochetman; M A Rayfield
Journal:  Emerg Infect Dis       Date:  1995 Jul-Sep       Impact factor: 6.883

8.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

9.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Authors:  A C Collier; R W Coombs; D A Schoenfeld; R L Bassett; J Timpone; A Baruch; M Jones; K Facey; C Whitacre; V J McAuliffe; H M Friedman; T C Merigan; R C Reichman; C Hooper; L Corey
Journal:  N Engl J Med       Date:  1996-04-18       Impact factor: 91.245

10.  Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients.

Authors:  R W Shafer; M A Winters; S Palmer; T C Merigan
Journal:  Ann Intern Med       Date:  1998-06-01       Impact factor: 25.391

View more
  13 in total

1.  Expression, purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease.

Authors:  Roxana M Coman; Arthur Robbins; Maureen M Goodenow; Robert McKenna; Ben M Dunn
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-03-30

2.  Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor.

Authors:  Meiqing Lu; Peter J Felock; Vandna Munshi; Renee C Hrin; Ying-Jie Wang; Youwei Yan; Sanjeev Munshi; Georgia B McGaughey; Robert Gomez; Neville J Anthony; Theresa M Williams; Jay A Grobler; Daria J Hazuda; Philip M McKenna; Michael D Miller; Ming-Tain Lai
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

3.  Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy.

Authors:  Patrícia A Brindeiro; Rodrigo M Brindeiro; Cláudio Mortensen; Kurt Hertogs; Veronique De Vroey; Norma P M Rubini; Fernando S Sion; Carlos A M De Sá; Deisy M Machado; Regina C M Succi; Amilcar Tanuri
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

4.  Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.

Authors:  S Weinheimer; L Discotto; J Friborg; H Yang; R Colonno
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.

Authors:  Ming-Tain Lai; Meiqing Lu; Peter J Felock; Renee C Hrin; Ying-Jie Wang; Youwei Yan; Sanjeev Munshi; Georgia B McGaughey; Robert M Tynebor; Thomas J Tucker; Theresa M Williams; Jay A Grobler; Daria J Hazuda; Philip M McKenna; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

6.  Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure.

Authors:  Ana T Dumans; Cláudia C Barreto; André F Santos; Mônica Arruda; Thatiana M Sousa; Elizabeth S Machado; Ester C Sabino; Rodrigo M Brindeiro; Amílcar Tanuri; Alberto J Duarte; Marcelo A Soares
Journal:  Infect Genet Evol       Date:  2008-10-17       Impact factor: 3.342

7.  Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.

Authors:  Krista A Delviks-Frankenberry; Renan B Lengruber; Andre F Santos; Jussara M Silveira; Marcelo A Soares; Mary F Kearney; Frank Maldarelli; Vinay K Pathak
Journal:  Virology       Date:  2012-10-13       Impact factor: 3.616

8.  Novel Mutations L228I and Y232H Cause Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Combinational Pattern.

Authors:  Xiao-Min Zhang; Qiwei Zhang; Hao Wu; Terrence Chi-Kong Lau; Xuan Liu; Hin Chu; Ke Zhang; Jie Zhou; Zhi-Wei Chen; Dong-Yan Jin; Bo-Jian Zheng
Journal:  AIDS Res Hum Retroviruses       Date:  2016-05-09       Impact factor: 2.205

9.  Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains.

Authors:  Susan H Eshleman; John Hackett; Priscilla Swanson; Shawn P Cunningham; Birgit Drews; Catherine Brennan; Sushil G Devare; Léopold Zekeng; Lazare Kaptué; Natalia Marlowe
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.

Authors:  N T Parkin; N S Hellmann; J M Whitcomb; L Kiss; C Chappey; C J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.